File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Oncostatic actions of melatonin

TitleOncostatic actions of melatonin
Authors
Issue Date2000
PublisherS Karger AG. The Journal's web site is located at http://www.karger.com/NSG
Citation
The 1999 International Symposium on Receptor and Non-Receptor Mediated Actions of Melatonin, Hong Kong, China, 6-8 November 1999. In Biological Signals and Receptors, 2000, v. 9 n. 1, p. 68 How to Cite?
AbstractIn the past few years, extensive interest has been aroused among the research community and the public on the potential of melatonin in the treatment of human diseases on which the current treatment options available are far from satisfactory. A distinct advantage of melatonin is its relative lack of adverse side effects, as demonstrated in animal and human studies, in comparison with many existing conventional drugs or pharmacological agents in development. The majority of findings in the scientific literature support a direct oncostatic action of melatonin on different types of cancer cells particularly by its anti-proliferative effect, despite occasional inconsistent or controversial results. Given that in many of these studies, the signalling mechanisms of melatonin responsible and the in vivo relevance of the in vitro observations to humans are still undefined, we have attempted to delineate the signalling mechanisms of melatonin on the modulation of cell proliferation of human choriocarcinoma and prostate cancer cells. Of note, melatonin was found to inhibit human choriocarcinoma Jar cell proliferation by delaying the transition of the cancer cells from G1 phase to S phase of the cell cycle and such anti-proliferative action of melatonin is likely to be mediated, in part, via MT2 receptors. Importantly, by demonstrating the expression of mt1 melatonin receptor in both LNCaP prostate cancer cells and human prostate cancer tissues from newly-diagnosed patients who have not received prior hormonal therapy and are presumably responsive to anti-androgen therapy, we have established the validity of using the androgen-sensitive LNCaP human prostate cancer cell line as a relevant cellular model for studying the effect of melatonin on androgen-responsive human prostate cancer. Furthermore, our data support the involvement of mt1 receptor and attenuated sex steroidinduced Ca2+ influx in mediating the direct anti-proliferative actions of melatonin on LNCaP cells. The available results suggest that melatonin is an attractive candidate molecule for future research and development as an anti-choriocarcinoma and anti-prostate cancer agent. The work described in this abstract was partially supported by a research grant from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. HKU 7069/ 99M)]
Descriptionpp. 53-75 of this journal issue entitled: Receptor and Non-Receptor Mediated Actions of Melatonin - International Symposium, Hong Kong, China, November 6-8, 1999
Persistent Identifierhttp://hdl.handle.net/10722/105192
ISSN
2003 Impact Factor: 3.5

 

DC FieldValueLanguage
dc.contributor.authorShiu, SYWen_HK
dc.date.accessioned2010-09-25T22:23:56Z-
dc.date.available2010-09-25T22:23:56Z-
dc.date.issued2000en_HK
dc.identifier.citationThe 1999 International Symposium on Receptor and Non-Receptor Mediated Actions of Melatonin, Hong Kong, China, 6-8 November 1999. In Biological Signals and Receptors, 2000, v. 9 n. 1, p. 68en_HK
dc.identifier.issn1422-4933en_HK
dc.identifier.urihttp://hdl.handle.net/10722/105192-
dc.descriptionpp. 53-75 of this journal issue entitled: Receptor and Non-Receptor Mediated Actions of Melatonin - International Symposium, Hong Kong, China, November 6-8, 1999-
dc.description.abstractIn the past few years, extensive interest has been aroused among the research community and the public on the potential of melatonin in the treatment of human diseases on which the current treatment options available are far from satisfactory. A distinct advantage of melatonin is its relative lack of adverse side effects, as demonstrated in animal and human studies, in comparison with many existing conventional drugs or pharmacological agents in development. The majority of findings in the scientific literature support a direct oncostatic action of melatonin on different types of cancer cells particularly by its anti-proliferative effect, despite occasional inconsistent or controversial results. Given that in many of these studies, the signalling mechanisms of melatonin responsible and the in vivo relevance of the in vitro observations to humans are still undefined, we have attempted to delineate the signalling mechanisms of melatonin on the modulation of cell proliferation of human choriocarcinoma and prostate cancer cells. Of note, melatonin was found to inhibit human choriocarcinoma Jar cell proliferation by delaying the transition of the cancer cells from G1 phase to S phase of the cell cycle and such anti-proliferative action of melatonin is likely to be mediated, in part, via MT2 receptors. Importantly, by demonstrating the expression of mt1 melatonin receptor in both LNCaP prostate cancer cells and human prostate cancer tissues from newly-diagnosed patients who have not received prior hormonal therapy and are presumably responsive to anti-androgen therapy, we have established the validity of using the androgen-sensitive LNCaP human prostate cancer cell line as a relevant cellular model for studying the effect of melatonin on androgen-responsive human prostate cancer. Furthermore, our data support the involvement of mt1 receptor and attenuated sex steroidinduced Ca2+ influx in mediating the direct anti-proliferative actions of melatonin on LNCaP cells. The available results suggest that melatonin is an attractive candidate molecule for future research and development as an anti-choriocarcinoma and anti-prostate cancer agent. The work described in this abstract was partially supported by a research grant from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. HKU 7069/ 99M)]-
dc.languageengen_HK
dc.publisherS Karger AG. The Journal's web site is located at http://www.karger.com/NSGen_HK
dc.relation.ispartofBiological Signals and Receptorsen_HK
dc.rightsBiological Signals and Receptors. Copyright © S Karger AG.en_HK
dc.titleOncostatic actions of melatoninen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1422-4933&volume=9&spage=68&epage=&date=2000&atitle=Oncostatic+actions+of+melatoninen_HK
dc.identifier.emailShiu, SYW: sywshiu@hkucc.hku.hken_HK
dc.identifier.authorityShiu, SYW=rp00384en_HK
dc.identifier.doi10.1159/000014623-
dc.identifier.hkuros51408en_HK
dc.identifier.volume9en_HK
dc.identifier.issue1-
dc.identifier.spage68en_HK
dc.identifier.epage68-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats